CFB siRNA (Human)

Référence MBS828328-30nmol

Conditionnement : 30nmol

Marque : MyBiosource

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

CFB siRNA – Complement Factor B Preproprotein (Human)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS828328

MBS828328 is an siRNA targeting CFB. Also known as CFB siRNA (Human). Reactive in Human. Host: Synthetic. siRNA to inhibit CFB expression using RNA interference More details

Product Overview

Online Datasheet in PDF
Product Name
CFB, siRNA
Full Product Name
CFB siRNA (Human)
Product Gene Name
CFB sirna
Product Synonym Names
BF; BFD; Complement factor B; C3/C5 convertase; Glycine-rich beta glycoprotein; GBG; PBF2; Properdin factor B
Host
Synthetic
Species Reactivity
Human
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
CFB siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
68,872 Da
OMIM
138470
3D Structure
ModBase 3D Structure for P00751
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CFB gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for CFB sirna
RNA Interference (RNAi)

Other Notes

Small volumes of CFB sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for CFB. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
complement factor B preproprotein
NCBI Official Synonym Full Names
complement factor B
NCBI Official Symbol
CFB
NCBI Official Synonym Symbols
BF; FB; BFD; GBG; CFAB; CFBD; PBF2; AHUS4; FBI12; H2-Bf; ARMD14
UniProt Protein Name
Complement factor B
UniProt Synonym Protein Names
C3/C5 convertase; Glycine-rich beta glycoprotein; GBG
Protein Family
Complement factor
UniProt Gene Name
CFB
UniProt Synonym Gene Names
BF; BFD; GBG
UniProt Entry Name
CFAB_HUMAN
NCBI Protein Information
complement factor B

NCBI Summary for CFB

This gene encodes complement factor B, a component of the alternative pathway of complement activation. Factor B circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the catalytic subunit Bb. The active subunit Bb is a serine protease which associates with C3b to form the alternative pathway C3 convertase. Bb is involved in the proliferation of preactivated B lymphocytes, while Ba inhibits their proliferation. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6. This cluster includes several genes involved in regulation of the immune reaction. Polymorphisms in this gene are associated with a reduced risk of age-related macular degeneration. The polyadenylation site of this gene is 421 bp from the 5' end of the gene for complement component 2. [provided by RefSeq, Jul 2008]
Show more

UniProt Comments for CFB

CFB: Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B- lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. Defects in CFB are a cause of susceptibility to hemolytic uremic syndrome atypical type 4 (AHUS4). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Belongs to the peptidase S1 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 3.4.21.47; Protease; Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 6p21.3

Cellular Component: extracellular space; plasma membrane; extracellular region

Molecular Function: complement binding; serine-type endopeptidase activity

Biological Process: complement activation, alternative pathway; regulation of complement activation; innate immune response; proteolysis; complement activation

Disease: Macular Degeneration, Age-related, 14; Complement Factor B Deficiency; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 4
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Products associated with CFB sirna

 Reference Product  PubMed Publications
 ARMS2 sirna  >44 publications with CFB and ARMS2
 C4B sirna  >4 publications with CFB and C4B
 CFP sirna  >3 publications with CFB and CFP

Pathways associated with CFB sirna

 Products by Pathway  Pathway Diagram
 Activation Of C3 And C5 Pathway antibodies  Activation Of C3 And C5 Pathway Diagram
 Alternative Complement Activation Pathway antibodies  Alternative Complement Activation Pathway Diagram
 Complement And Coagulation Cascades Pathway antibodies  Complement And Coagulation Cascades Pathway Diagram
 Complement And Coagulation Cascades Pathway antibodies  Complement And Coagulation Cascades Pathway Diagram
 Complement Cascade Pathway antibodies  Complement Cascade Pathway Diagram
 Immune System Pathway antibodies  Immune System Pathway Diagram
 Initial Triggering Of Complement Pathway antibodies  Initial Triggering Of Complement Pathway Diagram
 Innate Immune System Pathway antibodies  Innate Immune System Pathway Diagram
 Regulation Of Complement Cascade Pathway antibodies  Regulation Of Complement Cascade Pathway Diagram
 Staphylococcus Aureus Infection Pathway antibodies  Staphylococcus Aureus Infection Pathway Diagram

Diseases associated with CFB sirna

 Disease Name  Pubmed Publications
 Macular Degeneration Antibodies  >83 publications with CFB and Macular Degeneration
 Inflammation Antibodies  >26 publications with CFB and Inflammation
 Cardiovascular Diseases Antibodies  >24 publications with CFB and Cardiovascular Diseases
 Immune System Diseases Antibodies  >21 publications with CFB and Immune System Diseases
 Atypical Hemolytic Uremic Syndrome Antibodies  >17 publications with CFB and Atypical Hemolytic Uremic Syndrome
 Kidney Diseases Antibodies  >16 publications with CFB and Kidney Diseases
 Necrosis Antibodies  >15 publications with CFB and Necrosis
 Fibrosis Antibodies  >14 publications with CFB and Fibrosis
 Heart Diseases Antibodies  >11 publications with CFB and Heart Diseases
 Liver Diseases Antibodies  >11 publications with CFB and Liver Diseases

Organs/Tissues associated with CFB sirna

 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >83 publications with CFB and Blood
 Eye Antibodies  >67 publications with CFB and Eye
 Heart Antibodies  >36 publications with CFB and Heart
 Muscle Antibodies  >31 publications with CFB and Muscle
 Liver Antibodies  >26 publications with CFB and Liver
 Kidney Antibodies  >16 publications with CFB and Kidney
 Intestine Antibodies  >15 publications with CFB and Intestine
 Bone Antibodies  >13 publications with CFB and Bone
 Brain Antibodies  >9 publications with CFB and Brain
 Lung Antibodies  >8 publications with CFB and Lung